[go: up one dir, main page]

WO2003084991A1 - Proteines inductrices de dermatites atopiques - Google Patents

Proteines inductrices de dermatites atopiques Download PDF

Info

Publication number
WO2003084991A1
WO2003084991A1 PCT/JP2003/004325 JP0304325W WO03084991A1 WO 2003084991 A1 WO2003084991 A1 WO 2003084991A1 JP 0304325 W JP0304325 W JP 0304325W WO 03084991 A1 WO03084991 A1 WO 03084991A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
antibody
atopic dermatitis
peptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2003/004325
Other languages
English (en)
Japanese (ja)
Inventor
Michihiro Hide
Shoso Yamamoto
Toshihiko Tanaka
Osamu Koro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
Original Assignee
Japan Science and Technology Agency
Japan Science and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science and Technology Agency, Japan Science and Technology Corp filed Critical Japan Science and Technology Agency
Priority to JP2003582186A priority Critical patent/JPWO2003084991A1/ja
Priority to AU2003236374A priority patent/AU2003236374A1/en
Publication of WO2003084991A1 publication Critical patent/WO2003084991A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • Atopic dermatitis-inducing protein TECHNICAL FIELD
  • the invention of this application relates to an atopic dermatitis-inducing protein secreted by an atopic dermatitis patient himself, and an atopic dermatitis using this protein or its antibody. And a therapeutic agent for desensitization of atopic dermatitis comprising this protein as an active ingredient.
  • Atopic dermatitis is one of the atopic diseases caused by genetic factors that easily produce IgE antibodies against normal antigens.It begins in infancy, and chronically progresses with aging. Many relieve before puberty. The completed lesions are clearly lichenified, pruritus is always severe, often paroxysmal, and progresses and remits repeatedly with some association with other atopic diseases.
  • the invention of this application has been made in view of the above circumstances, and has as an object to provide an atopic dermatitis-inducing protein produced by a patient himself as a causative factor of atopic dermatitis. I have. It is another object of the invention of this application to provide a peptide which is a part of the protein and is involved in the antigenicity thereof.
  • Still another object of the invention of the present application is to provide a method for diagnosing atopic dermatitis using the above-mentioned protein and / or peptide or an antibody thereto. Further, another object of the invention of this application is to provide a therapeutic agent for desensitization of atopic dermatitis, which comprises the above-mentioned protein, protein or peptide as an active ingredient.
  • An atopic dermatitis-inducing protein which is a protein secreted from a human body and which binds to a human IgE antibody secreting the protein and activates mast cells and basophils.
  • the protein of the invention (1) secreted from salivary glands or sweat glands.
  • the protein according to the invention (1) or (2), wherein the protein is a Prolactin-inducible protein consisting of the amino acid sequence of SEQ ID NO: 4.
  • modified amino acid residue is one or more amino acid residues selected from the group consisting of lysine, arginine, methionine, alanine, phenylalanine, proline, asparagine, and tyrosine.
  • the protein according to the invention (8), wherein the protein is a Prolactin-inducible protein consisting of the amino acid sequence of SEQ ID NO: 4.
  • the protein according to the invention (9), wherein at least the 84th tyrosine residue of SEQ ID NO: 4 is methylated.
  • a method for diagnosing atopic dermatitis characterized in that the test is conducted to determine whether or not the subject has serum antibodies, and that the subject is determined to be a patient with atopic dermatitis or a high-risk atopic dermatitis.
  • the leukocyte fraction collected from the subject's blood contains one or more of the proteins of the inventions (1) to (10) or one or more of the peptides of the inventions (11) to (16)
  • a method for diagnosing atopic dermatitis comprising determining from the degree of histamine release a patient with atopic dermatitis or a subject at risk for atopic dermatitis.
  • a test is performed to determine whether or not a biological sample of a subject contains a protein that binds to one or more of the antibodies according to any one of the inventions (17) to (20).
  • a method for diagnosing atopic dermatitis comprising determining that the patient is a dermatitis patient or a high-risk person with atopic dermatitis.
  • An atopy characterized by containing, as an active ingredient, at least one of the proteins of the inventions (1) to (10) or at least one of the peptides of the inventions (11) to (16).
  • atopic dermatitis For desensitization of atopic dermatitis.
  • the aspects, terms and concepts in each of the inventions described above are defined in detail in the description of the embodiments of the invention and examples.
  • Various techniques used to carry out the present invention can be easily and reliably implemented by those skilled in the art based on known documents and the like, except for the technique whose source is clearly indicated.
  • the preparation of a drug that can be used for the treatment method of the present invention is described in Remington's Pharmaceutical Sciences, 18th Edition, ed. A.
  • the atopic dermatitis-inducing protein of the invention (1) is a protein secreted from a human body (particularly a sweat gland or salivary gland) of a human (particularly a patient with atopic dermatitis or a high-risk person thereof).
  • the protein of the present invention (1) specifically includes three different proteins.
  • the first is the protein of the invention (3), which is a protein having two or more identical amino acid repetitive sequences consisting of four or more amino acid residues S, and a more specific example thereof is the protein of the invention (4). That is, the protein of the invention (4) is a salivary acidic proline-rich phosphoprotein (hereinafter referred to as “PRP protein”) consisting of the amino acid sequence of SEQ ID NO: 2.
  • PRP protein salivary acidic proline-rich phosphoprotein
  • This PRP protein has nine QGPP repeats, four QGPPQQGG repeats, five PQGPP repeats, and three QQGPP repeats. Although the existence and structure of this PRP protein were known (for example, J. Biol. Chem. 260: 11123-11130, 1985, etc.), humans who secrete this PRP protein themselves It has not been known at all that it is an attractant protein that causes atopic dermatitis by binding to IgE antibodies and activating mast cells and basophils.
  • a second specific embodiment of the protein of the invention (1) is the protein of the invention (5), that is, a Prolactin-inducible protein consisting of the amino acid sequence of SEQ ID NO: 4 (hereinafter referred to as “PIP protein”).
  • a third specific embodiment of the protein of the invention (1) is the protein of the invention (6) (that is, a protein in which at least one of the constituent amino acid residues is post-translationally modified).
  • the modified amino acid residue is one or more amino acid residues selected from the group consisting of lysine, arginine, methionine, alanine, phenylalanine, proline, asparagine, and tyrosine
  • the modified group is an alkyl group. It is preferably a group.
  • a specific example of the protein of the present invention (6) is a PIP protein in which the 84th tyrosine residue in the amino acid sequence of SEQ ID NO: 4 is methylated (hereinafter sometimes referred to as “modified PIP protein”). It is.
  • any arginine residue in SEQ ID NO: 4 may be methylated. It has never been known that a PIP protein having such modified amino acid residues activates mast cells and basophils, thereby inducing atopic dermatitis.
  • the PRP protein and PIP protein, or the modified PIP protein can be isolated and purified from human sweat or saliva by the same method as in Example 1 described later. It can also be prepared by a method of chemically synthesizing the amino acid sequences of SEQ ID NOS: 2 and 4, respectively, by a known peptide synthesis method. Peptide synthesis can be performed using various solid phase methods (see, for example, Science 269: 202, 1995; Methods Enzymol. 289: 3-13, 1997), and also, for example, ABI431A peptide synthesizer.
  • RNA is prepared by in vitro transcription from a recombinant expression vector having the aforementioned DNA sequence
  • the protein can be produced in vitro by performing in vitro translation using this as a type III.
  • prokaryotic cells such as Escherichia coli and Bacillus subtilis
  • eukaryotic cells such as yeast, insect cells, and mammalian cells to produce transformed cells
  • DNA sequences from the transformed cells are obtained. Can be prepared.
  • RNA polymerase promoter When a protein is expressed by in vitro translation, the above DNA sequence is inserted into a vector having an RNA polymerase promoter to prepare a recombinant expression vector, and this vector is used as an RNA corresponding to the promoter.
  • the protein can be produced in vitro by adding it to an in vitro translation system, such as a persimmon reticulocyte lysate or wheat germ extract containing polymerase.
  • an in vitro translation system such as a persimmon reticulocyte lysate or wheat germ extract containing polymerase.
  • the RNA polymerase promoter include T7, T3, and SP6.
  • vectors containing these RNA polymerase promoters include pKA1, pCDM8, pT3 / T718, ⁇ 7 / 319, pBluescript II, and the like.
  • This in vitro transcription / translation method is one of the preferred methods for producing a PIP protein in which at least the 84th tyrosine residue (and any arginine residue) is methylated.
  • a microorganism such as Escherichia coli
  • the above-described expression vector having an origin, a promoter, a liposome binding site, a DNA cloning site, and a mine that can be replicated in the microorganism is used.
  • a target protein can be obtained from a microorganism by preparing an expression vector in which the DNA sequence is recombined, transforming a host cell with this expression vector, and culturing the resulting transformant.
  • a fusion protein with another protein for example, a fusion protein with glutatin? S? Transferase? (GST) or green fluorescent protein (GFP)
  • GST glutatin? S? Transferase?
  • GFP green fluorescent protein
  • expression vectors for Escherichia coli include a pUC system, pBluescript II, a pET expression system, a pGEX expression system, and the like.
  • the recombinant vector is inserted by inserting the protein into the expression vector for eukaryotic cells having the DNA sequence, promoter, splicing region, poly (A) addition site, and the like. Once produced and introduced into eukaryotic cells, It can be obtained from transformed eukaryotic cells.
  • expression vectors examples include pKAl, pCDM8, pSVK3, pMSG, pSVL, pBK-CMV, pBK-RSV, EBV vector, pRS, pcDNA3, pMSG, pYES2, and the like.
  • pIND / V5-His, pFLAG-CMV-2, pEGFP-Nl, pEGFP-Cl, etc. are used as expression vectors, fusion with various tags such as His-tag, FLAG-tag, myc-tag, HA-tag, GFP etc.
  • the desired protein can also be expressed as a protein.
  • eukaryotic cells monkey kidney cells COS7, mammalian cells such as Chinese ovarian ovary cells CHO and the like, budding yeast, fission yeast, silkworm cells, African egg cells and the like are generally used. Any eukaryotic cell can be used as long as it can express E. coli.
  • known methods such as an electroporation method, a calcium phosphate method, a ribosome method, and a DEAE dextran method can be used.
  • isolation and purification of the target protein from the culture can be performed by a combination of known separation procedures. .
  • denaturing agents such as urea or surfactants, sonication, enzyme digestion, salting-out / solvent precipitation, dialysis, centrifugation, ultrafiltration, gel filtration, SDS-PAGE, isoelectric focusing Ion chromatography, hydrophobic chromatography, affinity chromatography, reverse phase chromatography and the like.
  • the serum of the dermatitis patient is allowed to react with the protein, and the protein that binds to the antibody in the serum may be selected.
  • the invention (11) of the present application is a peptide which is a part of the atopic dermatitis-inducing protein of the invention (1) and which comprises an amino acid sequence constituting a binding region (antigenic determinant or epitope) to an IgE antibody. is there. This peptide can be obtained by degrading the protein of the invention (1) with an appropriate protease.
  • This peptide is specifically a peptide (invention (12)) which is a part of the protein of the invention (31 or (4), the protein of the invention (5) A peptide (Invention (4)) which is a part of the protein; and a peptide (Invention (15)) which is a part of the protein of any of Inventions (6) to (10). More specifically, they are PRP proteins and peptides as a part of PIP proteins (Inventions (13) and (16)). In the case of a peptide as a part of a PRP protein or a PIP protein, a peptide having a desired amino acid sequence can be obtained by a known peptide synthesis method based on SEQ ID NOS: 2 and 4, respectively.
  • the coding region of the desired peptide is cleaved from the DNA sequence of SEQ ID NO: 1 or 3, or PCR is amplified, and the peptide is produced from this DNA sequence by the genetic engineering method as described above. You can also.
  • the proteins of the inventions (1) to (10) bind to two or more antibodies by having two or more epitopes, and thereby exert physiological activities. Therefore, the peptides of the inventions (11), (12), (14 ⁇ ), and (16) can include amino acid sequences constituting two or more epitope regions.
  • atopic dermatitis-inducing activity proteins (1) to (10)
  • it is useful, for example, as an active ingredient of the desensitizing therapeutic agent of the invention (24).
  • the peptide of the present invention may have one epitope.
  • Such a peptide can be used as an antigen for producing an antibody or as a material for the diagnostic method of the inventions (21) and (22).
  • the peptide derived from the PRP protein is a peptide containing at least the four consecutive amino acid sequences of SEQ ID NO: 2, for example, a region containing the amino acid repeat sequence of SEQ ID NO: 2 (amino acids Nos. 47 to 158).
  • the peptide derived from the PIP protein is preferably a continuous 4-amino acid sequence or more including the 84th tyrosine residue that has been methylated in the amic acid sequence of SEQ ID NO: 4. More preferably, the methylated tyrosine residue at position 84 and any arginine residue that may be methylated (ie, the second, ninth, 33rd, 47th, 106th, 118th, and 136th arginine residues).
  • Invention (17) is an antibody prepared using the protein of invention (1) or the peptide of invention (11) as an antigen.
  • the antibodies of the inventions (18) to (20) are antibodies prepared using the protein of the inventions (3) to (10) or the peptide of the inventions (12) to (16) as antigens, respectively.
  • These antibodies are polyclonal antibodies or monoclonal antibodies, and include all molecules capable of binding to each of the above-mentioned protein epitopes, Fab, F (ab ') 2 , Fv fragments and the like.
  • Fab fragment antigen binding to each of the above-mentioned protein epitopes
  • F (ab ') 2 fragment fragments and the like.
  • Fv fragments fragments and the like.
  • a polyclonal antibody such an antibody can be obtained from serum after immunizing an animal using an antigen peptide or a partial fragment thereof as an immunogen.
  • mice can be prepared by introducing the above expression vector for eukaryotic cells into the muscle or skin of an animal by injection or gene gun, and then collecting serum.
  • animals mice, lads, egrets, goats, and chickens are used.
  • Monoclonal antibodies can be prepared by a known monoclonal antibody preparation method (“monoclonal antibody”, written by Kamei Nagamune and Hiroshi Terada, Hirokawa Shoten, 1990; “Monoclonal Antibody”, James W. Goding, third edition, Academic Press, 1996). According to this, for example, it can be manufactured by the following procedure. Preparation of doma cell group
  • a mammal is immunized with the above-mentioned atopic dermatitis-inducing protein or epitope peptide as an antigen (immunogen), and boosted as necessary to sensitize the animal.
  • antibody-producing cells lymphocytes or spleen cells
  • a fusion cell of this and a myeloma (myelotype) cell line is obtained.
  • the protein of the invention (1) to ( ⁇ ) or the peptide of the invention (11) to (16) is appropriately added It can be selected as an immunogen.
  • immunogens can also be used in the form of fusion proteins with other proteins (for example, Daryuthion-1S-transferase: GST).
  • the use of such a fusion protein is particularly preferable in that the isolation of the target protein from the expression product of the host-vector system and the screening step of eight hybridoma cells described later are easy and reliable.
  • Successful antibody production using a short-chain peptide as an antigen is described in, for example, the following literature (Biochem. J. 266: 497-504, 1990; Biochem. J. 288: 195-205). , 1992, Molecular and Cellular Biology 8: 2159-2163, 1988).
  • mice As the animal to be immunized, a mammal used in a known method for producing eight hybridomas can be used. Specifically, for example, mice, rats, goats, sheep, whales, horses, etc. However, from the viewpoint of availability of myeloma cells to be fused with the extracted antibody-producing cells, it is preferable to use mice or rats as immunized animals.
  • the strains of mice and rats actually used are not particularly limited.
  • mice for example, strains A, AKR, BALB / c, BDP, BA, CE, C3H, 57BL, C57BR, C57L, DBA , FL, HTH, HT1, LP, NZB, NZW, RF, REL SJL, SWR, WB, 129, etc.
  • rats for example, Low, Lewis, Spraque, Daley, ACL BN, Fischer etc.
  • the BALB / c strain in mice and the low strain in rats are particularly preferred as animals to be immunized, considering the compatibility with myeloma cells described below.
  • the age of the mouse or rat at the time of immunization is preferably 5 to 12 weeks.
  • Immunization of an animal can be performed by administering a solution of the immunogen intradermally or intraperitoneally to the animal.
  • the administration schedule of the immunogen varies depending on the type of the animal to be immunized, individual differences, and the like.
  • the dose of the antigen varies depending on the type of animal, individual differences, and the like, but is generally about 10-100 ig / ml. cj cell fusion
  • Antibody production from the immunized animal 1 to 5 days after the last immunization date in the above administration schedule Spleen cells or lymph cells, including live cells, are aseptically removed.
  • the antibody-producing cells can be separated from these spleen cells or lymph cells according to a known method.
  • the myeloma cells are not particularly limited, and can be appropriately selected from known cell lines and used. However, in consideration of the convenience in selecting eight hybridomas from the fused cells, it is preferable to use an HGPRT-deficient HGPRT-hypoxanthine-guanine phosphoribosyl transferase (defective) strain that has established its selection procedure.
  • the fusion of the antibody-producing cell and the myeloma cell can be appropriately performed according to a known method, under conditions that do not extremely reduce the cell viability.
  • a chemical method of mixing antibody-producing cells and myeloma cells in a high-concentration polymer solution such as polyethylene glycol or a physical method using electrical stimulation can be used.
  • the selection of fused cells and non-fused cells is preferably performed, for example, by a known HAT (hypoxanthine'aminopterin thymidine) selection method.
  • HAT hyperxanthine'aminopterin thymidine
  • This method is effective when obtaining fusion cells using myeloma cells of an HGPRT-deficient strain that cannot survive in the presence of aminopterin. That is, by culturing the unfused cells and the fused cells in the HAT medium, only the fused cells having aminobuterin resistance can be selectively left and grown.
  • Hybridoma screening is preferably performed, for example, by a known HAT (hypoxanthine'aminopterin thymidine) selection method. This method is effective when obtaining fusion cells using myeloma cells of an HGPRT-deficient strain that cannot survive in the presence of aminopterin. That is, by culturing the unfused cells and the fused cells in the HAT medium,
  • Screening of hybridoma cells producing the desired monoclonal antibody can be performed by known enzyme immunoassay (EIA: Enzyme Immunoassay), radioimmunoassay (RIA: Radio Immunoassay), fluorescent antibody method, etc. .
  • EIA Enzyme Immunoassay
  • RIA Radio Immunoassay
  • fluorescent antibody method etc.
  • a fusion protein is used as an immunogen, the fusion partner protein
  • the hybridoma cells after screening are cloned by a known method such as a methylcellulose method, a soft agarose method, or a limiting dilution method, and used for antibody production.
  • the hybridoma cells obtained by the above-mentioned method can be stored in liquid nitrogen or at -80 in the following freezer in a frozen state.
  • the desired monoclonal antibody can be obtained by culturing the hybridoma cells prepared in 1 above by a known method.
  • the culture may be performed, for example, in the medium having the same composition used in the cloning method described above, or in order to produce a large amount of monoclonal antibodies, inject the hybridoma cells into the mouse intraperitoneal cavity, and use Antibodies may be collected.
  • the monoclonal antibody thus obtained can be purified by, for example, ammonium sulfate precipitation, gel filtration, ion exchange chromatography, affinity chromatography, or the like.
  • the invention (21) is characterized by using at least one of the proteins of the inventions (1) to (10) or one or more of the peptides of the inventions (11) to (16) to obtain an atopic property. This is a method to diagnose dermatitis.
  • the proteins of the inventions (1) to (10) have been identified as proteins that bind to antibodies (IgE antibodies) in the serum of patients with atopic dermatitis, and the inventions (11) to (16) Is a peptide containing an epitope of these proteins, it is reacted with the serum of the subject, and the serum containing an antibody that binds to these proteins or peptides is used as the serum of a patient with atopic dermatitis or a high-risk patient with atopic dermatitis. Can be determined.
  • the serum of a subject is brought into contact with the above-described protein or peptide, and the protein or peptide is reacted with the IgE antibody in the serum of the subject in a liquid phase.
  • a signal of the labeled anti-IgE antibody may be detected by reacting with a labeled anti-IgE antibody that specifically binds to the IgE antibody in the serum. Enzymes, radioisotopes, and fluorescent dyes can be used as the labeling substance of the labeled anti-IgE antibody.
  • the enzyme is not particularly limited as long as it satisfies conditions such as a high turnover number, stability even when bound to an anti-IgE antibody, and specific coloring of the substrate.
  • peroxidase / 3-galactosidase, alkaline phosphatase, glucose oxidase, acetylcholinesterase, glucose 16-phosphoryl dehydrogenase, malate dehydrogenase and the like can also be used.
  • the binding between these enzymes and the anti-IgE antibody can be performed by a known method using a crosslinking agent such as a maleimide compound.
  • a known substance can be used depending on the type of the enzyme to be used.
  • peroxidase when using peroxidase as an enzyme, use 3,3 ', 5,5'-tetramethylbenzine, and when using alkaline phosphatase, use paranitrophenol or the like. it can.
  • radioactive isotope those used in ordinary RIA such as i 25 I and 3 H can be used.
  • Fluorescent dyes include those used in ordinary fluorescent methods such as fluorescein isothiocyanate (FITC) and tetramethylrhodamine isothiocyanate (TRITC), as well as fluorescent proteins such as green fluorescent protein. You can use any quality.
  • the signal is detected by adding a substrate that decomposes and develops color by the action of the enzyme, and measuring the amount of decomposition of the substrate optically to determine the enzyme activity, which is converted to the amount of bound antibody. Then, the amount of the antibody is calculated from the comparison with the standard value.
  • radioisotopes measure the radiation dose emitted by the radioisotope using a scintillation counter.
  • the amount of fluorescence may be measured by a measuring device combined with a fluorescence microscope.
  • Samples for signal detection include Western blot analysis and protein conjugate + serum antibody + labeled anti-IgE antibody conjugate using well-known separation means (chromatography, salting out, alcohol precipitation, enzymatic method). , Solid phase method, etc.) and the signal of the labeled anti-IgE antibody may be detected.
  • the diagnostic method of the invention (21) can also immobilize one or more types of protein peptides on a plate, and test the binding of the subject serum to the antibody on the plate. By immobilizing the protein / peptide on the plate, unbound labeled binding molecules can be easily removed.
  • the method of the present invention (21) enables not only the diagnosis of atopic dermatitis but also the quantification of the amount of an antibody to be detected.
  • the method of the invention (22) is characterized in that the leukocyte fraction collected from the blood of the subject contains at least one of the proteins of the inventions (1) to (10) or the peptide of the inventions (11) to (16) At least one or more is added to distinguish patients with atopic dermatitis or high-risk atopic dermatitis using the degree of histamine release from leukocytes as an index.
  • the histamine released by the stimulation of the protein of the invention (1) to (10) or the peptide of the invention (11) to (16) causes atopic dermatitis.
  • the amount of histamine can be measured, for example, by a known method (Koro, O. et al. J. Allergy Clin. Immunol., 103, 663-670, 1999).
  • a criterion for diagnosis for example, the amount of increase in histamine released when a leukocyte fraction collected from a subject is stimulated with the protein or peptide is 5% or more as compared with that without stimulation.
  • Invention (23) tests whether a biological sample of a subject contains a protein that binds to one or more antibodies of any of inventions (17) to (2), and examines whether the protein is present in the sample. It is characterized in that a person is determined to be a patient with atopic dermatitis or a person at high risk for atopic dermatitis. That is, the antibodies of the inventions (17) to (20) are antibodies that specifically bind to the proteins of the inventions (1) to (10), and the proteins of the inventions (1) to (10) are atopic dermatitis. Therefore, a biological sample containing a protein that binds to this antibody can be determined as a sample of an atopic dermatitis patient or a high-risk patient thereof.
  • the biological sample may be any sample isolated from a subject, but saliva or sweat is particularly preferred.
  • One embodiment of the diagnostic method of the present invention (23) is a method of binding an antibody and a protein in a liquid phase system.
  • an antibody labeled with a labeling substance as exemplified in the invention (21) is brought into contact with a biological sample to bind the labeled antibody to a target protein, and this conjugate is treated in the same manner as in the invention (21).
  • the labeled signal is recovered in a similar manner.
  • Another method of diagnosis in a liquid phase system involves contacting an antibody (primary antibody) with a biological sample to bind the primary antibody to the target protein, and then binding a labeled antibody (secondary antibody) to the conjugate.
  • an unlabeled secondary antibody may be first bound to the antibody + protein conjugate, and a labeling substance may be bound to this secondary antibody.
  • binding of the labeling substance to the secondary antibody can be performed, for example, by biotinylating the secondary antibody and avidinizing the labeling substance. Or a partial region of the secondary antibody
  • An antibody (a tertiary antibody) recognizing (for example, an Fc region) may be labeled, and the tertiary antibody may be bound to the secondary antibody.
  • both monoclonal antibodies can be used, or one of the primary antibody and the secondary antibody can be a polyclonal antibody. Separation of the conjugate from the liquid phase and detection of a signal can be performed in the same manner as in the invention (21).
  • Another embodiment of the diagnostic method of the invention (23) is a method of testing the binding between an antibody and a target protein in a solid phase system. This method using a solid phase system is a preferred method because detection of a trace amount of protein and simplification of the operation are preferable.
  • an antibody in this solid phase method, an antibody (primary antibody) is immobilized on a resin plate or the like, the target protein is bound to the immobilized antibody, and the unbound protein is washed off, and then left on the plate.
  • a labeled antibody secondary antibody
  • This method is a so-called “sandwich method”, and is widely used as “ELISA (enzyme linked immunosorbent assay)” when an enzyme is used as the primary method.
  • ELISA enzyme linked immunosorbent assay
  • the detection of the signal can be performed in the same manner as in the invention (21).
  • the method of the present invention (23) enables not only the diagnosis of atopic dermatitis but also the quantification of the amount of atopic dermatitis-inducing protein.
  • a standard calibration curve, etc.
  • Invention (24) is characterized by containing, as an active ingredient, at least one of the proteins of inventions (1) to (10) and / or at least one of the peptides of inventions (11) to (16).
  • Desensitization treatment means that in allergy involving IgE antibodies, a small amount of therapeutic allergen is administered in increasing doses over a certain number of days, so that no allergic reaction occurs even if the allergen enters This is a cure. Since the proteins of the inventions (1) to (10) and the peptides of the inventions (11) to (16) have the activity of inducing atopic dermatitis as described above, they are used in the treatment for desensitization. For allergens.
  • the peptide is preferably a peptide having two or more epitope regions like a protein and exhibiting the same physiological activity as that of the protein (attractable dermatitis-inducing activity). It may be a peptide having an epitope region (so-called “hapten”).
  • the therapeutic agent for desensitization of the present invention (23) can be formulated by uniformly mixing the above-mentioned protein nopeptide with a pharmacologically acceptable carrier.
  • the carrier can be appropriately selected from a wide range depending on the dosage form of the drug, but the drug of the present invention is desirably in a unit dosage form that can be administered orally or by injection.
  • Oral liquid preparations such as suspensions and syrups include water, sugars such as sucrose, sorbitol, fructose, glycols such as polyethylene glycol, oils such as sesame oil and soybean oil, and preservatives such as alkyl parahydroxybenzoate. It can be manufactured using a flavoring agent such as an agent, stroberberry flavor, peppermint and the like. Powders, pills, capsules and tablets include lactose, glucose, sugar, mannitol and other excipients, starch, disintegrants such as sodium alginate, magnesium stearate, talc, etc.
  • a binder such as polyvinyl alcohol, hydroxypropyl cellulose and gelatin, a surfactant such as fatty acid ester, and a plasticizer such as glycerin.
  • Tablets and capsules are preferred unit dosage forms in the formulations of the present invention in that they are easy to administer.
  • a solid pharmaceutical carrier is used.
  • the solution for injection can be formulated using a carrier comprising a salt solution, a glucose solution, a mixture of a saline solution and a glucose solution, various buffers and the like.
  • the composition may be formulated in a powder state, and mixed with the liquid carrier before use to prepare an injection solution.
  • the administration schedule of the desensitizing therapeutic agent of the present invention varies depending on the patient's age, body weight, symptoms, administration route, and the like.
  • the amount of protein Z peptide as a therapeutic allergen is determined by performing an intradermal test in advance, and It is preferable to measure the threshold value at the initial dose and to use the amount before and after the threshold value as the first dose.
  • the administration interval and the amount of increase in allergen after the second administration can be appropriately determined depending on the presence or degree of allergic reaction. Eventually, allergens that are about 10,000 times the threshold dose can be administered.
  • the hyposensitizing drug of this invention if the initial dose of allergen is formulated as lng / ml X 0.05 ml, the final dose of the drug is 10 mg / ml X 0.05 ml.
  • the invention of this application will be described more specifically and in detail with reference to examples, but the invention of this application is not limited to the following examples.
  • Sweat was collected from several healthy persons or patients with atopic dermatitis, and the target antigen protein was purified using histamine release from peripheral blood basophils as a marker for patients with atopic dermatitis.
  • Sweat was collected from several healthy persons or patients with atopic dermatitis in a sauna bath, and the residue was removed with filter paper.
  • the residue was diluted with 20 mM Tris buffer (pH 8.0) and sterilized by filtration with a 0.02 im filter.
  • fractionate sweat diluted with an anion exchange resin column (monoQHR10 / 10, Amersham Pharmacia Biotec), and dilute the fraction containing the target protein with 20 mM acetate buffer (pH 4.75).
  • fractionation was performed using a cation exchange resin column (monoS HR5 / 5, Amersham Pharmacia Biotec).
  • the fraction containing the protein of interest was diluted with 20 mM Tris buffer (pH 8.0) and fractionated on an anion exchange resin column (monoQSP1.6 / 5, Amersham Pharmacia Biotec) using the SMART system.
  • the fraction containing the protein of interest was collected, diluted 10-fold with a 0.1% aqueous solution of trifluoroacetic acid, and further fractionated on a reversed-phase column (RPC C2 / C 18, Amersham Pharmacia Biotec).
  • RPC C2 / C 18, Amersham Pharmacia Biotec reversed-phase column
  • This fraction was subjected to a mass spectrometer Q-TOF (Micromass) to obtain protein
  • the partial sequence of the amino acid was determined.
  • the amino acid sequence ai matched human salivary acidic proline-rich Ohosphoprotein (PRP).
  • the modified Proptin-inducible protein (PIP) and the modified PIP in which the 84th tyrosine was methylated were confirmed. It was also confirmed that at least one arginine residue was methylated in this modified PIP.
  • the mass corresponding to tyrosine and arginine contained mass having a mass 14 daltons larger than the theoretical molecular weight of each. Turned out to be.
  • Recombinant PRP 100 / ig prepared in Example 2 was subcutaneously administered with Freund's complete adjuvant to the back skin of 4-week-old NZW Pergum, and three weeks later, recombinant PRP lOO jtig was subcutaneously administered with Freund's incomplete adjuvant. .
  • recombinant PRP100 g was subcutaneously administered together with Freund's complete adjuvant, and three days later, blood was collected from the auricular artery.
  • the IgG fraction was purified using a protein G column, and the antibody titer was measured by immunoassay using an immobilized recombinant PRP immobilized plate to prepare a rabbit heron anti-PRP polyclonal antibody.
  • mice Preparation of mouse anti-PRP monoclonal antibody
  • the recombinant PRP prepared in Example 2 was mixed with Freund's complete adjuvant and administered intraperitoneally to the mouse.Two weeks later, the recombinant PRP was mixed with Freund's incomplete adjuvant. The mice were administered intraperitoneally. Two weeks later, recombinant PRP was intraperitoneally administered, and three days later, immunized mice were sacrificed by transection of the vertebrae, and the spleen was removed. The removed spleen was crushed on a nylon mesh, and RPMI culture solution was used.
  • Cell suspension c c Separately prepared mouse myeloma cell line Sp2 / 0-Agl4 cells were fused with splenocytes and polyethylene glycol and cultured in HAT medium. The fused cells (Eighty-brown dorma) were selectively cultured on a micro-tie plate. When colony formation can be confirmed under an inverted microscope, a part of the culture supernatant is collected, The binding to the antigen was confirmed by immunoassay. Pairs of cells in which binding to the antigen was confirmed were recovered, subjected to limiting dilution, and cultured in a microplate.
  • the cells of the gel showing positive results in immunoassay were collected, and the antibody-producing cells were collected again as a single clone by limiting dilution.
  • This monoclonal cell line was cultured in large quantities, the culture supernatant was applied to a Tin G column, and the IgG fraction was affinity purified. The binding to PRP was confirmed by ELISA and Western blotting, and an anti-PRP monoclonal antibody was prepared.
  • the PIP cDNA (PIPmat DNA) excluding the signal sequence was introduced into a mammalian expression vector (pME18S; Proc Natl Acad Sci US A. 89 (12): 5206-52 10, 1992) to obtain The resulting plasmid (pME18S-PIPmat) was transfected into COS-7 cells. Subsequently, a large amount of the recombinant cells (COS-PIPmat) were cultured, and the insoluble fraction was removed from the culture supernatant by centrifugation to obtain a fraction containing the recombinant PIPmat. Similarly, only the pME18S vector was transfected into COS-7 cells as a control, and the supernatant (imock) was prepared.
  • pME18S Proc Natl Acad Sci US A. 89 (12): 5206-52 10, 1992
  • the recombinant PRP prepared in Example 2 was diluted to 1-5 ig / ml with phosphate buffer buffer (PBS), and the solution was added to all wells of a microtiter plate. Noted. After shaking at room temperature for 2 hours, the plate was washed twice with 0.02% Tween / PBS (T-PBS). 3% BSA / PBS solution was added to block nonspecific binding sites, and the mixture was shaken at room temperature for 2 hours. After washing twice with T-PBS, 100 / il of the serum of the subject diluted to various concentrations with 3% BSA / PBS was added and shaken for 2 hours.
  • PBS phosphate buffer buffer
  • an HRP-labeled anti-human IgE antibody solution was added, shaken at room temperature for 2 hours, and washed twice with T-PBS. A few minutes after adding the chromogenic substrate, it was confirmed that the color had developed, a stop solution was added, and the HRP signal was detected with a plate reader.
  • the anti-PIP monoclonal antibody prepared in Example 6 was diluted with PBS and —Dispensed to After leaving at room temperature for 2 hours, the plate was washed twice with T-PBS, then a 3% BSA / PBS solution was added for blocking nonspecific binding sites, shaken at room temperature for 2 hours, and washed twice with PBS. Add the sweat sample to each well, shake for 2 hours at room temperature, wash twice with ⁇ -PBS, add anti-PRP ⁇ sagi polyclonal antibody diluted with T-PBS, shake for 2 hours at room temperature, Washed twice with T-PBS.
  • the protein (PIP) binding to the anti-PIP monoclonal antibody was detected at a higher concentration in the sweat samples of patients with atopic dermatitis than in the sweat samples of healthy subjects.
  • Histamine-releasing activity of recombinant PRP and PIP The recombinant PRP prepared in Example 2 and the recombinant PIP prepared in Example 3 were further purified by reversed-phase columns (C2 / C18) using the FPLC system (SMART). did. As a result, the main peak appeared in the same fraction as the elution site of hissamine release activity when the sweat component was purified by the same column. In addition, histamine releasing activity from peripheral blood basophils of atopic dermatitis patients was detected in the fraction. The fraction was electrophoresed on SDS-PAGE and detected as a single band at 17 kD.
  • the present invention also provides a method for diagnosing atopic dermatitis using the above-mentioned protein and Z or a peptide, and a therapeutic agent for desensitization of atopic dermatitis using the same as an active ingredient. This makes it possible to diagnose with high accuracy the degree of the symptoms and the risk of developing atopic dermatitis, and to make effective treatment possible.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des protéines inductrices de dermatites atopiques produites par le patient lui même et identifiées comme en étant le facteur déclenchant. Lesdites protéines, sécrétées par le corps humain, sont caractérisé en ce quelles se fixent au propre anticorps de l'IgE du producteur humain, et activent les mastocytes et les basophiles. Plus spécifiquement, lesdites protéines comportent une phosphoprotéine salivaire acide riche en proline présentant la séquence d'acides aminés SEQ ID NO: 2 , une protéine induite par la prolactine présentant la séquence d'acides aminés SEQ ID NO: 4, et ses modifications post traductionnelle.
PCT/JP2003/004325 2002-04-08 2003-04-04 Proteines inductrices de dermatites atopiques Ceased WO2003084991A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2003582186A JPWO2003084991A1 (ja) 2002-04-08 2003-04-04 アトピー性皮膚炎誘引蛋白質
AU2003236374A AU2003236374A1 (en) 2002-04-08 2003-04-04 Atopic dermatitis-inducing proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002105425 2002-04-08
JP2002-105425 2002-04-08

Publications (1)

Publication Number Publication Date
WO2003084991A1 true WO2003084991A1 (fr) 2003-10-16

Family

ID=28786382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/004325 Ceased WO2003084991A1 (fr) 2002-04-08 2003-04-04 Proteines inductrices de dermatites atopiques

Country Status (3)

Country Link
JP (1) JPWO2003084991A1 (fr)
AU (1) AU2003236374A1 (fr)
WO (1) WO2003084991A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005474A1 (fr) 2003-07-09 2005-01-20 Shionogi & Co., Ltd. Inducteur de dermatite atopique
WO2009133951A1 (fr) 2008-05-02 2009-11-05 国立大学法人 広島大学 Anticorps monoclonal anti-antigène de transpiration
WO2014027626A1 (fr) * 2012-08-17 2014-02-20 国立大学法人広島大学 ANTICORPS MONOCLONAL IgE SE LIANT À LA PROTÉINE ANTIGÉNIQUE À L'ORIGINE DE L'ALLERGIE À LA SUEUR
US9457071B2 (en) 2012-06-28 2016-10-04 Hiroshima University Histamine releaser contained in human sweat

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034579A1 (fr) * 1994-06-14 1995-12-21 Pharmacia Ab Molecules de recombinaison, proteines/polypeptides, systemes hotes et methodes pour diagnostiquer et traiter l'atopie
WO2002026962A1 (fr) * 2000-09-26 2002-04-04 Genox Research, Inc. Procede d'examen de maladies allergiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034579A1 (fr) * 1994-06-14 1995-12-21 Pharmacia Ab Molecules de recombinaison, proteines/polypeptides, systemes hotes et methodes pour diagnostiquer et traiter l'atopie
WO2002026962A1 (fr) * 2000-09-26 2002-04-04 Genox Research, Inc. Procede d'examen de maladies allergiques

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
MAEDA N. ET AL.: "Differential RNA splicing and post-translational cleavages in the human salivary proline-rich protein gene system", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 260, no. 20, 1985, pages 11123 - 11130, XP002217688 *
MURPHY L.C. ET AL.: "Isolation and sequencing of a cDNA clone for a prolactin-inducible protein (PIP). Regulation of PIP gene expression in the human breast cancer cell line, T-47D", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 262, no. 31, 1987, pages 15236 - 15241, XP002969518 *
NATTER S. ET AL.: "Isolation of cDNA clones coding for IgE autoantigens with serum IgE from atopic dermatitis patients", FASEB JOURNAL, vol. 12, no. 14, 1998, pages 1559 - 1569, XP002969522 *
VALENTA R. ET AL.: "Autoallergy: a pathogenetic factor in atopic dermatitis?", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 105, no. 3, March 2000 (2000-03-01), pages 432 - 437, XP002969520 *
VALENTA R. ET AL.: "Isolation of cDNAs coding for IgE autoantigens: a link between atopy and autoimmunity", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, vol. 113, no. 1-3, 1997, pages 209 - 212, XP002969521 *
VALENTA R. ET AL.: "Molecular characterization of an autolallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 111, no. 6, December 1998 (1998-12-01), pages 1178 - 1183, XP002969519 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005474A1 (fr) 2003-07-09 2005-01-20 Shionogi & Co., Ltd. Inducteur de dermatite atopique
KR101156523B1 (ko) 2003-07-09 2012-06-20 시오노기세야쿠 가부시키가이샤 아토피성 피부염 유도 물질
WO2009133951A1 (fr) 2008-05-02 2009-11-05 国立大学法人 広島大学 Anticorps monoclonal anti-antigène de transpiration
US8546542B2 (en) 2008-05-02 2013-10-01 Hiroshima University Anti-sweat antigen monoclonal antibody
JP5924752B2 (ja) * 2008-05-02 2016-05-25 国立大学法人広島大学 抗汗抗原モノクローナル抗体
US9457071B2 (en) 2012-06-28 2016-10-04 Hiroshima University Histamine releaser contained in human sweat
US9709576B2 (en) 2012-06-28 2017-07-18 Hiroshima University Histamine releaser contained in human sweat
WO2014027626A1 (fr) * 2012-08-17 2014-02-20 国立大学法人広島大学 ANTICORPS MONOCLONAL IgE SE LIANT À LA PROTÉINE ANTIGÉNIQUE À L'ORIGINE DE L'ALLERGIE À LA SUEUR
JPWO2014027626A1 (ja) * 2012-08-17 2016-07-25 国立大学法人広島大学 汗アレルギー抗原蛋白質に結合するモノクローナルＩｇＥ抗体
US9989538B2 (en) 2012-08-17 2018-06-05 Hiroshima University Monoclonal IgE antibody that binds to sweat allergy antigen protein

Also Published As

Publication number Publication date
JPWO2003084991A1 (ja) 2005-08-11
AU2003236374A1 (en) 2003-10-20

Similar Documents

Publication Publication Date Title
US10464976B2 (en) Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
JP4824547B2 (ja) モノクローナル抗体およびその利用
SK12872003A3 (sk) Nádorové signálne znaky rakovinového nádoru obličkovej bunky
Aden et al. Standardization of Alternaria alternata: extraction and quantification of alt a 1 by using an mAb-based 2-site binding assay
WO2015048929A1 (fr) Marqueurs pour le cancer du sein
KR19990044226A (ko) 후천성 부갑상선기능감퇴증 환자의 자가항체 및 그의 분석방법
WO2003084991A1 (fr) Proteines inductrices de dermatites atopiques
KR101777254B1 (ko) En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
KR101458483B1 (ko) 신장암 진단 조성물 및 키트
AU2015253282A1 (en) Methods and compositions for screening and detecting cancer
US6187549B1 (en) Protein as a diagnostic of cancer
JP3983260B2 (ja) アトピー性皮膚炎誘引物質
AU2003227862B2 (en) An EPHRIN-B receptor protein involved in carcinoma
EP3686286B1 (fr) Biomarqueur du cancer de l'ovaire et son utilisation
Zahra Adyel et al. Characterization of autoantibody activities in sera anti‐DNA antibody and circulating immune complexes from 12 systemic lupus erythematosus patients
JP2003300961A (ja) 新規ピリジニウム誘導体およびその利用方法
JP2007071849A (ja) 中皮腫診断剤および中皮腫診断キット
KR102307043B1 (ko) Wasf2 자가항체를 이용한 간세포암종 조기진단용 조성물
JP2016141666A (ja) 新規アレルゲンおよびその使用
WO1994010205A1 (fr) Proteine specifique de la maladie d'alzheimer et procede de diagnostic de cette maladie par detection de ladite proteine
WO2018155793A1 (fr) Peptide de fragment immunogène d'une protéine en2 ou composition d'anticorps reconnaissant spécifiquement ledit peptide
TWI702400B (zh) 偵側卵巢癌之方法、監控卵巢癌病患之卵巢癌發展之方法及可辨識切割型c3多胜肽之試劑的用途
JP2003259872A (ja) ヒト食道癌抗原ペプチドと食道癌診断方法
JPWO2005056597A1 (ja) 免疫グロブリンＦｃ受容体タンパク質
JP5261708B2 (ja) 抗８−チオアルコキシグアノシン−３’，５’−サイクリック１リン酸抗体

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003582186

Country of ref document: JP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase